Nucletron   Report issue

For profit Phase 2
Founded: Veenendaal Netherlands (1975)
Status: Acquired by Elekta (2011)

Organization Overview

First Clinical Trial
2013
NCT02017704
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

capecitabine (xeloda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1